Search | Clinical Trials Finder

Conditions: Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions: Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P; Diagnostic Test · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Endometrial Cancer
Interventions: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 13 more

Conditions: Human Immunodeficiency Virus
Interventions: 3BNC117, 10-1074, Analytical treatment interruption; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Antibodies
Interventions: VRC-HIVMAB091-00-AB, rHuPH20; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer
Interventions: MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel; Drug
Lead sponsor: BioNTech Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Fort Myers, Florida • Wichita, Kansas • Williamsville, New York

Conditions: Metastatic Melanoma
Interventions: Ipilimumab, Tilsotolimod with Ipilimumab; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym023; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ublituximab, Umbralisib, Venetoclax; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 50
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab); Drug
Lead sponsor: Multitude Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Port Saint Lucie, Florida • Kingwood, Texas

Conditions: Multiple Myeloma, Leukemia, Lymphoma
Interventions: Fludarabine, Melphalan, Umbilical Cord Blood, Rituximab, Peripheral Blood Stem Cell Infusion; Drug · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Nivolumab, Docetaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 30
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 23 more

Conditions: Neuroblastoma
Interventions: beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
Interventions: Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, CliniMACS System; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more

Conditions: Primary Immune Deficiency Diseases (PIDD)
Interventions: 10% IGIV; Biological
Lead sponsor: Evolve Biologics; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Centennial, Colorado • Tampa, Florida + 7 more

Conditions: Immunoglobulin A Nephropathy (IgAN)
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 37
States / cities: Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 33 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10%; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more

Conditions: Endometrial Cancer, Malignant Solid Tumour
Interventions: Puxitatug Samrotecan, Doxorubicin, Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 69
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 60 more

Conditions: Arthritis, Rheumatoid
Interventions: ABP 798, Rituximab (US), Rituximab (EU); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 27
States / cities: Tuscaloosa, Alabama • Los Angeles, California • Thousand Oaks, California + 24 more

Conditions: Spinocerebellar Ataxias
Interventions: Intravenous Immune Globulin (IVIG); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

3BNC117 and 10-1074 in ART-treated Individuals

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Cellular Therapy With Cord Blood Cells

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Study of PlasmaCap IG in Adults and Children With PIDD

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias